Last quarter (Q1 2023), Carl Zeiss Meditec's total revenue was €470.30M, an increase of 4.84% from the same quarter last year. In Q1, Carl Zeiss Meditec's net income was €51.00M. See Carl Zeiss Meditec’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Sep 23	Sep 22	Sep 21	Sep 20	Sep 19
Total Revenue	€ 1.80B	-	€ 1.90B	€ 1.65B	€ 1.34B	€ 1.46B
Cost of Revenue	€ 787.50M	-	€ 775.24M	€ 679.57M	€ 589.93M	€ 627.44M
Gross Profit	€ 1.04B	-	€ 1.13B	€ 967.21M	€ 745.52M	€ 831.88M
Operating Expense	€ 706.39M	-	€ 730.72M	€ 593.60M	€ 567.97M	€ 567.23M
Operating Income	€ 336.23M	-	€ 396.88M	€ 373.61M	€ 177.55M	€ 264.66M
Net Non Operating Interest Income Expense	€ 30.33M	-	€ 55.24M	€ -9.46M	€ -3.29M	€ -6.15M
Other Income Expense	-	-	-	-	-	-
Pretax Income	€ 335.53M	-	€ 403.49M	€ 339.05M	€ 178.72M	€ 229.86M
Tax Provision	€ 92.94M	-	€ 107.58M	€ 101.53M	€ 55.30M	€ 69.28M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	€ 242.16M	-	€ 293.91M	€ 236.28M	€ 122.39M	€ 159.76M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	€ 1.49B	-	€ 1.51B	€ 1.27B	€ 1.16B	€ 1.19B
Net Income From Continuing And Discontinued Operation	€ 242.16M	-	€ 293.91M	€ 236.28M	€ 122.39M	€ 159.76M
Normalized Income	€ 242.16M	-	€ 293.91M	€ 236.28M	€ 122.39M	€ 159.76M
Interest Expense	€ 9.19M	-	€ 9.59M	€ 9.37M	€ 27.89M	€ 8.21M
EBIT	€ 344.72M	-	€ 413.08M	€ 348.42M	€ 206.60M	€ 238.07M
EBITDA	€ 344.72M	€ 501.88M	€ 482.85M	€ 410.00M	€ 267.03M	€ 286.44M

Currency in EUR

Carl Zeiss Meditec Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing